Mumbai, 13 November (Udaipur Kiran)। Entero Healthcare Solutions shares traded higher on Thursday after the company announced board approval to acquire a majority 80% stake in Bioaide Technologies, a medical device distribution firm aligned with its core business.
The stock was quoted at ₹1186.80, up ₹49.40 or 4.34% from its previous close of ₹1137.40. It opened at ₹1159.85 and hit an intraday high of ₹1200.00. Total traded volume stood at 12,889 shares.
The BSE ‘B’ group stock has a 52-week high of ₹1564.95 (5 Feb 2025) and a 52-week low of ₹1038.80 (7 Nov 2025). The company’s market capitalization is ₹5,143.19 crore. Promoters hold 52.42%, institutions 24.32%, and non-institutions 23.26%.
Acquisition to Strengthen Medical Distribution Portfolio
Entero’s board has approved definitive agreements to acquire an 80% stake in Bioaide Technologies, which operates in wholesale distribution of medical devices and allied products. The acquisition is expected to be completed by 15 February 2026.
Additionally, the board has cleared entering into a binding MoU to acquire a 51% stake in Anand Chemiceutics, subject to due diligence and final agreements.
Entero Healthcare Solutions operates a technology-driven distribution platform supplying healthcare products to pharmacies, hospitals, and clinics across India.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
